Understand the source comparison
Best Research Peptides for Mitochondrial Dysfunction: Mechanism Comparison
Before you begin. This table compares mechanism, target site, and research application for each peptide. The 'Professional Assessment' column addresses when each peptide is most appropriate and when it's not. SS-31 (Elamipretide) Cardiolipin stabilization Inne
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Before you begin. This table compares mechanism, target site, and research application for each peptide. The 'Professional Assessment' column addresses when each peptide is most appropriate and when it's not.
- SS-31 (Elamipretide)
- Cardiolipin stabilization
- Inner mitochondrial membrane
- Acute injury (ischemia-reperfusion, stroke, heart failure exacerbation)
- Best for preserving existing mitochondrial function under oxidative stress. Not effective for biogenesis or metabolic reprogramming. Timing is critical: post-injury administration shows minimal benefit.
- MOTS-C
- AMPK activation, nuclear transcription
- Cytoplasm → nucleus → mitochondrial biogenesis
- Metabolic disease (insulin resistance, obesity, type 2 diabetes models)
- Strongest in models where metabolic inflexibility is the primary dysfunction. Less effective in acute injury where immediate ATP preservation is needed. Requires 48–72 hours to show transcriptional effects.
- Humanin
- STAT3-mediated anti-apoptosis, Bax inhibition
- Outer mitochondrial membrane, cytoplasm
- Neurodegenerative disease (Alzheimer's, Parkinson's, ALS models)
- Prevents cell death signaling but doesn't reverse existing damage. Early intervention is essential. Metabolic benefits are secondary to cytoprotection, so it's less appropriate for pure metabolic dysfunction models.
- NAD+ precursors (NMN, NR)
- NAD+ repletion, sirtuin activation
- Entire mitochondrial network
- Aging models, chronic low-grade dysfunction
- Effective for restoring NAD+/NADH ratio when deficiency is confirmed. Not a first-line choice if membrane integrity or apoptosis is the primary issue. Dosing must account for tissue-specific NAD+ kinase activity.
- Mitoquinone (MitoQ)
- Targeted antioxidant delivery
- Inner membrane (lipophilic cation delivery)
- Oxidative stress models without structural membrane damage
- Works as a reactive oxygen species scavenger. Doesn't address metabolic signaling or apoptosis. Best used when oxidative damage is isolated and reversible, not when cristae structure is already compromised.